Novo Nordisk A/S (NONOF)

122,50 -0,31 (-0,25 %) À la clôture : 03:57PM EDT

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 63 370

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Lars Fruergaard Jorgensen	President, CEO & Member of Management Board	4,61M	S.O.	1966
Mr. Karsten Munk Knudsen	Executive VP, CFO & Member of the Management Board	1,83M	S.O.	1971
Mr. Henrik Ehlers Wulff	Executive VP of Product Supply, Quality & IT and Member of the Management Board	1,84M	S.O.	1970
Ms. Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	1,8M	S.O.	1972
Dr. Martin Holst Lange	Executive VP of Development & Member of the Management Board	1,74M	S.O.	1970
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board	1,74M	S.O.	1966
Mr. Maziar Mike Doustdar	Executive VP of International Operations & Member of the Management Board	S.O.	S.O.	1970
Mr. Douglas J. Langa	Executive VP of North America Operations & Member of Management Board	S.O.	S.O.	1966
Mr. Ludovic Helfgott	Executive VP, Head of Rare Disease & Member of Management Board	S.O.	S.O.	1974
Ms. Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	S.O.	S.O.	1977

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Novo Nordisk A/S en date du 1 avril 2024 est 1. Les scores principaux sont Audit : 2; Société : 2; Droits des actionnaires : 9; Compensation : 1.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.